Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
9.5
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2025年1月1日〜2025年9月30日ConsolidatedJapanese GAAPNet Sales14,987¥ millionYear on year +9.5%Progress 73.8%
Operating profit4,247¥ millionYear on year +16.4%Progress 77.2%
Ordinary income4,361¥ millionYear on year +17.9%Progress 77.2%
Net income attributable to owners of the parent3,329¥ millionYear on year +26.7%Progress 77.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share179.53円
Financial position at period-end
Total assets34,292¥ million
of which net assets 28,312 ¥ millionEquity ratio 82.6%vs. prior year-end +1.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueJapan ¥5,542 million (YoY +1.2%), Taiwan ¥2,821 million (YoY +14.4%), Zhuhai (China) ¥2,006 million (YoY +17.8%), Suzhou (China) ¥2,807 million (YoY +4.3%), Europe ¥1,052 million (YoY +43.1%), Thailand ¥757 million (YoY +24.8%)
Segment profitJapan ¥2,765 million (YoY +2.0%), Taiwan ¥342 million (YoY +4.0%), Zhuhai (China) ¥262 million (YoY -14.9%), Suzhou (China) ¥376 million (YoY -13.9%), Europe ¥89 million (YoY +676.8%), Thailand ¥128 million (YoY +67.7%)
Regional sales¥5,542 million (YoY +1.2%), ¥2,821 million (YoY +14.4%), ¥2,006 million (YoY +17.8%), ¥2,807 million (YoY +4.3%), ¥1,052 million (YoY +43.1%), ¥757 million (YoY +24.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥20,300 million (YoY +11.3%)
Operating profit¥5,500 million (YoY +20.5%)
Ordinary income¥5,650 million (YoY +20.7%)
Net income¥4,300 million (YoY +87.6%)
Revision to Earnings ForecastNet Sales Not disclosed → ¥20,300 million / Operating profit Not disclosed → ¥5,500 million / Ordinary income Not disclosed → ¥5,650 million / Net income Not disclosed → ¥4,300 million
Annual Dividend Forecast¥45 → ¥85
Factors Behind Changes in Business Performance
生成AI関連など先端半導体パッケージ基板、パソコンやスマートフォン向けの製品需要が堅調に推移したことにより薬品売上高が増加した。薬品出荷量の増加と収益性の高い製品需要により営業利益が増加し、為替の影響等で経常利益が増加した。補助金収入の計上等により親会社株主に帰属する四半期純利益が増加した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Material subsequent eventsNot applicable.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥4,237 thousand, Subsidy Income ¥546,447 thousand / Extraordinary loss Loss on sale of fixed assets ¥338 thousand, Loss on Disposal of Fixed Assets ¥150,108 thousand
Depreciation and amortization¥602,656 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End19,571,093
Treasury Shares at Period-End1,310,362
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年1月1日〜2025年9月30日 |
| Net Sales | ¥14,987 million (YoY +9.5%) |
| Operating profit | ¥4,247 million (YoY +16.4%) |
| Ordinary income | ¥4,361 million (YoY +17.9%) |
| Profit attributable to owners of the parent | ¥3,329 million (YoY +26.7%) |
| Net income per share | 179.53円 |
| Equity ratio | End of the current fiscal period 82.6 / End of previous period 81.4 |
| Total assets | ¥34,292 million |
| Net assets | ¥28,312 million |
| Full-year earnings forecast | Net Sales ¥20,300 million (YoY +11.3%) / Operating profit ¥5,500 million (YoY +20.5%) / Ordinary income ¥5,650 million (YoY +20.7%) / Net income ¥4,300 million (YoY +87.6%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥20,300 million / Operating profit Not disclosed → ¥5,500 million / Ordinary income Not disclosed → ¥5,650 million / Net income Not disclosed → ¥4,300 million |
| Annual Dividend Forecast | ¥45 → ¥85 |
| Segment revenue | Japan ¥5,542 million (YoY +1.2%), Taiwan ¥2,821 million (YoY +14.4%), Zhuhai (China) ¥2,006 million (YoY +17.8%), Suzhou (China) ¥2,807 million (YoY +4.3%), Europe ¥1,052 million (YoY +43.1%), Thailand ¥757 million (YoY +24.8%) |
| Segment profit | Japan ¥2,765 million (YoY +2.0%), Taiwan ¥342 million (YoY +4.0%), Zhuhai (China) ¥262 million (YoY -14.9%), Suzhou (China) ¥376 million (YoY -13.9%), Europe ¥89 million (YoY +676.8%), Thailand ¥128 million (YoY +67.7%) |
| Regional sales | ¥5,542 million (YoY +1.2%), ¥2,821 million (YoY +14.4%), ¥2,006 million (YoY +17.8%), ¥2,807 million (YoY +4.3%), ¥1,052 million (YoY +43.1%), ¥757 million (YoY +24.8%) |
| Depreciation and amortization | ¥602,656 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥4,237 thousand, Subsidy Income ¥546,447 thousand / Extraordinary loss Loss on sale of fixed assets ¥338 thousand, Loss on Disposal of Fixed Assets ¥150,108 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 19,571,093 |
| Treasury Shares at Period-End | 1,310,362 |
| Factors Behind Changes in Business Performance | 生成AI関連など先端半導体パッケージ基板、パソコンやスマートフォン向けの製品需要が堅調に推移したことにより薬品売上高が増加した。薬品出荷量の増加と収益性の高い製品需要により営業利益が増加し、為替の影響等で経常利益が増加した。補助金収入の計上等により親会社株主に帰属する四半期純利益が増加した。 |
Items this document does not state (9)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.生成AI関連など先端半導体パッケージ基板向け製品やパソコン・スマートフォン向けの需要が堅調に推移し、薬品出荷量が増加したこと、収益性の高い製品の需要が堅調であったことから営業利益が増加した。経常利益は為替の影響等により増加し、親会社株主に帰属する四半期純利益は補助金収入の計上等により増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.